Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381969 | 0.89 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1GLAMAPTGAA | |
| SCHEMBL13381695 | 0.89 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1GAA | |
| SCHEMBL13381525 | 0.89 | ADAM33 (0.47) | L3MBTL1ALDH1A1GLAMAPTGAA | |
| SCHEMBL2841104 | 0.85 | TP53 (0.47) | L3MBTL1LMNAKMT2A | |
| SCHEMBL13381499 | 0.81 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1GAA | |
| SCHEMBL13381614 | 0.80 | MAPT (0.49) | L3MBTL1ALDH1A1GLAMAPTGAA | |
| SCHEMBL13381621 | 0.80 | TSHR (0.58) | ALDH1A1MAPTLMNA | |
| SCHEMBL13381505 | 0.80 | TSHR (0.60) | ALDH1A1LMNA | |
| SCHEMBL13381741 | 0.80 | MMP2 (0.42) | L3MBTL1MAPTMEN1LMNAHTT | |
| SCHEMBL13381622 | 0.79 | GAA (0.52) | L3MBTL1ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010039911-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-08 | — | — | WO | disclosed |